Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

2.2K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.2K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

2.3K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.3K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

5.3K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

849
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
849
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

1.1K
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chromatographic resolution and reliable quantification of eleven endogenous and microbiota-derived tryptophan metabolites in human plasma by HPLC-MS/MS.

Journal of chromatography. A·2026
Same author

Fraisinib in a Shell: Liposomal Encapsulation of a GARS1 Inhibitor for Controlled Anticancer Delivery.

AAPS PharmSciTech·2026
Same author

Beyond translation: systematic insight of the multifaceted roles of GARS1 in cellular biology and disease.

Cell cycle (Georgetown, Tex.)·2025
Same author

USP7 at the Crossroads of Ubiquitin Signaling, Cell Cycle, and Tumorigenesis.

Molecules (Basel, Switzerland)·2025
Same author

Ap4A in Cancer: A Multifaceted Regulator and Emerging Therapeutic Target.

Molecules (Basel, Switzerland)·2025
Same author

Long-term benefits of TUDCA supplement in ARSACS zebrafish model.

Scientific reports·2025

Related Experiment Video

Updated: Nov 20, 2025

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay
05:17

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Published on: February 9, 2021

1.8K

Bicyclic Basic Merbarone Analogues as Antiproliferative Agents.

Andrea Spallarossa1, Matteo Lusardi1, Chiara Caneva1

  • 1Department of Pharmacy, University of Genova, Viale Benedetto XV, 3, 16132 Genova, Italy.

Molecules (Basel, Switzerland)
|January 26, 2021
PubMed
Summary

Novel pyrimido-pyrimidine analogues were synthesized and tested for antiproliferative activity. While derivatives 5d and 5e showed promise, their efficacy was lower than previous compounds, with poor topoisomerase IIα interaction observed for 5d.

Keywords:
antiproliferative agentsdocking simulationpyrimido-pyrimidine derivativesstructure activity relationships (SAR) study

More Related Videos

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.5K
Efficient Construction of Drug-like Bispirocyclic Scaffolds Via Organocatalytic Cycloadditions of α-Imino γ-Lactones and Alkylidene Pyrazolones
10:17

Efficient Construction of Drug-like Bispirocyclic Scaffolds Via Organocatalytic Cycloadditions of α-Imino γ-Lactones and Alkylidene Pyrazolones

Published on: February 7, 2019

7.1K

Related Experiment Videos

Last Updated: Nov 20, 2025

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay
05:17

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Published on: February 9, 2021

1.8K
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.5K
Efficient Construction of Drug-like Bispirocyclic Scaffolds Via Organocatalytic Cycloadditions of α-Imino γ-Lactones and Alkylidene Pyrazolones
10:17

Efficient Construction of Drug-like Bispirocyclic Scaffolds Via Organocatalytic Cycloadditions of α-Imino γ-Lactones and Alkylidene Pyrazolones

Published on: February 7, 2019

7.1K

Area of Science:

  • Medicinal Chemistry
  • Molecular Biology
  • Drug Discovery

Background:

  • Pyrimido-pyrimidine derivatives serve as rigid analogues of merbarone.
  • Previous studies demonstrated their potent antiproliferative activity and topoisomerase IIα inhibition.

Purpose of the Study:

  • To synthesize and evaluate novel pyrimido-pyrimidine analogues.
  • To further elucidate structure-activity relationships (SAR) for this compound class.

Main Methods:

  • Two-step synthesis of novel pyrimido-pyrimidine analogues.
  • Evaluation of antiproliferative activity.
  • Molecular docking studies with topoisomerase IIα.

Main Results:

  • Analogues 3-6 were synthesized with variations in alkyl groups, a 4-chlorophenyl substituent, and basic side chains.
  • Antiproliferative activity was influenced by side chain and scaffold substituents.
  • Derivatives 5d and 5e exhibited reduced antiproliferative activity compared to prior analogues.
  • Docking studies revealed poor interaction and altered orientation of 5d within the topoisomerase IIα complex.

Conclusions:

  • The nature of substituents significantly impacts the antiproliferative potential of pyrimido-pyrimidine derivatives.
  • Derivatives 5d and 5e represent promising leads but require further optimization.
  • Understanding ligand-enzyme interactions is crucial for designing effective topoisomerase IIα inhibitors.